I-Sec initiates coverage on Suven Pharmaceuticals with a Buy rating, target price Rs 1,400 Jobbery Stock Market update

ICICI Securities recommends buying Suven Pharmaceuticals with a target price of Rs 1,400. The firm exhibits strong quarterly growth, reporting a net profit of Rs 83.29 crore. Suven is predicted to show significant growth in revenue, EBITDA, and PAT over the next years, with expectations of improving RoE and substantial free cash flow generation.